In a new study from Radboud University, researchers found 75% of the COVID-19 survivors who were treated in the Intensive Care Unit (ICU) experience physical, mental, and/or cognitive problems one-year post ICU.
In the study, the health status of ICU survivors is monitored with questionnaires up to five years after ICU admission.
The study regarding long-term health problems was conducted among 246 COVID-19 patients (176 men/70 women) who were treated in the intensive care unit (ICU) in the Netherlands.
Their mean age was 61 years. Using questionnaires, they were asked how they were doing one-year post ICU. Worldwide, this is the first scientific research regarding long-term problems among COVID-19 ICU survivors.
Patients in this study were admitted to the ICU during the first COVID-19 surge between March and July 2020.
The team found that three-quarters of the COVID-19 ICU survivors experience problems one-year post ICU. These are primarily physical problems, whereby half of the patients experience feelings of fatigue.
Other physical problems are e.g. a reduced condition, pain, muscle weakness, and shortness of breath. Also, mental symptoms are common; one in five COVID-19 ICU survivors experience feelings of anxiety or post-traumatic stress.
Furthermore, one in six have cognitive problems such as memory or attention problems.
These various problems negatively affect former ICU patients’ daily lives.
Over half of them indicate that they have work-related problems because of the health problems: they reduced their working hours; they are still on sick leave or have even given up their job.
This study shows what an incredible impact an ICU admission has on the lives of former COVID-19 patients. Even after one year, half of them are tired or experience a lack of energy to fully resume their work.
If you care about COVID, please read studies that drug combo can effectively fight COVID-19, and novel vaccine method to prevent COVID-19 infection.
For more information about Covid, please see recent studies about the cause of severe disease and death in COVID-19, and results showing this low-cost drug can treat COVID-19 effectively and safely.
The study is published in the journal JAMA and was conducted by Marieke Zegers et al.
Copyright © 2022 Knowridge Science Report. All rights reserved.
